je.st
news
Home
› GE Healthcare Files Supplemental New Drug Application For Its Own Manufacturing Of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)
GE Healthcare Files Supplemental New Drug Application For Its Own Manufacturing Of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)
2013-01-15 13:50:00| drugdiscoveryonline News Articles
GE Healthcare recently announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility
Tags: application
files
drug
manufacturing
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||